Aldafermin治疗NASH合并代偿期肝硬化的随机双盲安慰剂对照试验
这项多中心双盲安慰剂对照2b期试验纳入160例代偿期NASH肝硬化患者,随机接受Aldafermin 0.3mg、1mg、3mg或安慰剂治疗48周。主要终点为增强肝纤维化评分变化,3mg组较安慰剂组显著降低(差值-0.5,95%CI -0.7至-0.2,p=0.0003)。
要点
- 3mg Aldafermin组48周增强肝纤维化评分较安慰剂组显著降低。
- 纤维化改善≥1期比例:安慰剂15%、1mg组21%、3mg组23%。
- 腹泻是最常见不良事件,1mg组26%、3mg组40%,安慰剂组18%。
核心结论
- Aldafermin 3mg可显著降低代偿期NASH肝硬化患者的增强肝纤维化评分。
研究设计与样本
- 多中心、双盲、安慰剂对照、2b期试验,160例代偿期NASH肝硬化患者随机分为Aldafermin 0.3mg组(n=7)、1mg组(n=42)、3mg组(n=55)或安慰剂组(n=56),治疗48周;0.3mg组因限制亚优剂量暴露而终止。
主要发现
- 第48周时,3mg组与安慰剂组增强肝纤维化评分变化的 least-squares 均值差为-0.5(95%CI -0.7至-0.2;p=0.0003)。
- 纤维化改善≥1期比例:安慰剂组15%、1mg组21%、3mg组23%;纤维化改善≥1期且NASH无恶化比例:安慰剂组13%、1mg组16%、3mg组20%。
- 丙氨酸氨基转移酶、天冬氨酸氨基转移酶、III型胶原新表位特异性N端前肽及肝脏硬度改善在Aldafermin组优于安慰剂组。
- 腹泻发生率:1mg组26%、3mg组40%,安慰剂组18%;因治疗相关不良事件停药比例:安慰剂组0%、1mg组2%、3mg组9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. APPROACH AND RESULTS: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was -0.5 (95% CI, -0.7 to -0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. CONCLUSIONS: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.
引用
- Rinella ME, Lieu HD, Kowdley KV, et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2023. PMID: 37732990. doi:10.1097/HEP.0000000000000607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。